Cargando…

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen

BACKGROUND: Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Cetuximab manufactured by ImClone (US commercial cetuximab) potentially results in higher...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soulières, Denis, Aguilar, Jose Luis, Chen, Eric, Misiukiewicz, Krzysztof, Ernst, Scott, Lee, Hyun Jung, Bryant, Katherine, He, Shuang, Obasaju, Coleman K., Chang, Shao-Chun, Chin, Steve, Adkins, Douglas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714495/ https://www.ncbi.nlm.nih.gov/pubmed/26768732 http://dx.doi.org/10.1186/s12885-016-2064-0

Ejemplares similares

Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer
por: Borel, Christian, et al.
Publicado: (2018)

Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report
por: Mesía, Ricard, et al.
Publicado: (2010)

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
por: Berger, Bernhard, et al.
Publicado: (2008)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment
por: Galbiati, Donata, et al.
Publicado: (2019)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer
por: Posch, Doris, et al.
Publicado: (2016)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
por: Zhang, Mengping, et al.
Publicado: (2020)

A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer
por: Hecht, Markus, et al.
Publicado: (2021)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution
por: de Mello, Ramon Andrade, et al.
Publicado: (2014)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018)

An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer
por: Cavalieri, Stefano, et al.
Publicado: (2022)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
por: Kurokawa, Marie, et al.
Publicado: (2015)

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
por: Mesía, R., et al.
Publicado: (2010)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response
por: De Azevedo, Justine, et al.
Publicado: (2022)

Cetuximab in Refractory Skin Cancer Treatment
por: Kalapurakal, Sini J, et al.
Publicado: (2012)

A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
por: De Vita, F, et al.
Publicado: (2011)

Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study
por: Tanioka, Hiroaki, et al.
Publicado: (2018)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer
por: Zhang, Zhan-Dong, et al.
Publicado: (2014)

Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies
por: Perez, Raymond P., et al.
Publicado: (2019)

Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling
por: Chang, Jae Won, et al.
Publicado: (2015)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
por: Noronha, Vanita, et al.
Publicado: (2017)

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience
por: Adams, R A, et al.
Publicado: (2009)

Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma
por: Tai, Cheng-Jeng, et al.
Publicado: (2016)

Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2022)

Stereotactic body radiotherapy plus cetuximab for previously irradiated un-resectable head and neck cancer
por: Huang, Tai-Lin, et al.
Publicado: (2022)

Severe Acneiform Eruption Induced by Cetuximab (Erbitux®)
por: Lee, Jung Eun, et al.
Publicado: (2008)

Evolving role of cetuximab in the treatment of colorectal cancer
por: Schuch, Gunter, et al.
Publicado: (2009)

Allergic/infusion reactions reported with cetuximab and rituximab
por: Wolf, Ray A, et al.
Publicado: (2015)

Cetuximab-Associated Crescentic Diffuse Proliferative Glomerulonephritis
por: Manthri, Sukesh, et al.
Publicado: (2017)

p16, HPV, and Cetuximab: What Is the Evidence?
por: Bonner, James A., et al.
Publicado: (2017)

PRSS contributes to cetuximab resistance in colorectal cancer
por: Tan, Zhaoli, et al.
Publicado: (2020)

Acute Generalized Exanthematous Pustulosis Induced by Cetuximab
por: Masood, Sadia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_78clmhbi3f8d4ank1ulk3c3u5p